Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.

@article{Walther1998SerumIL,
  title={Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.},
  author={med. Markus Walther and Bernadette Elaine Johnson and Dennis E. Culley and Rajal Shah and Jeffrey S. Weber and David J Venzon and James C Yang and W. Marston Linehan and Steven A Rosenberg},
  journal={The Journal of urology},
  year={1998},
  volume={159 3},
  pages={
          718-22
        }
}
PURPOSE We sought to determine the frequency of interleukin-6 (IL-6) expression in renal cancer cell lines, the frequency of the detection of IL-6 in the serum of patients with metastatic renal cell carcinoma, whether serum IL-6 level correlates with the development of paraneoplastic syndromes and whether serum IL-6 level in patients with metastatic renal cancer correlates with response to treatment with interleukin-2 (IL-2) or patient survival. MATERIALS AND METHODS Conditioned media from 21… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Similar Papers

Loading similar papers…